Catalyst Pharmaceuticals (CPRX) Operating Margin (2018 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Operating Margin came in at 49.02% in Q1 2026, up 421.0% YoY from 9.41% in Q1 2025, and up 20.96% on a QoQ basis from 40.52% in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Operating Margin (2018 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 9 years of Operating Margin data on file, last reported at 49.02% in Q1 2026.
- Quarterly Operating Margin rose 421.0% year-over-year to 49.02% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 44.83% (up 156.0% YoY) and the FY2025 annual result came in at 43.77%, up 409.0% from the prior year.
- Operating Margin climbed to 49.02% in Q1 2026, from 40.52% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 53.79% in Q2 2022 to a low of 36.21% in Q3 2023.
- A 5-year average of 38.74% and a median of 44.21% in 2024 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2023 — Operating Margin sank 8007 bps — and 2024, when it surged 7577 bps.
- Tracing CPRX's Operating Margin over 5 years: stood at 50.7% in 2022, then dropped by 26 bps to 37.71% in 2023, then rose by 18 bps to 44.31% in 2024, then fell by 9 bps to 40.52% in 2025, then gained by 21 bps to 49.02% in 2026.
- The last three Operating Margin figures came in at 49.02% (Q1 2026), 40.52% (Q4 2025), and 44.66% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 49.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.02% |
| Dec 31, 2025 | 40.52% |
| Sep 30, 2025 | 44.66% |
| Jun 30, 2025 | 45.24% |
| Mar 31, 2025 | 44.81% |
| Dec 31, 2024 | 44.31% |
| Sep 30, 2024 | 39.56% |
| Jun 30, 2024 | 44.21% |
| Mar 31, 2024 | 27.54% |
| Dec 31, 2023 | 37.71% |
| Sep 30, 2023 | -36.21% |
| Jun 30, 2023 | 46.90% |
| Mar 31, 2023 | 41.71% |
| Dec 31, 2022 | 50.70% |
| Sep 30, 2022 | 43.85% |
| Jun 30, 2022 | 53.79% |
| Mar 31, 2022 | 40.30% |
| Dec 31, 2021 | 33.26% |
| Sep 30, 2021 | 38.95% |
| Jun 30, 2021 | 43.55% |